Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Price:
7.86 USD
-1.13%
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
ARQT
stock under the Base Case scenario is
13.1
USD.
Compared to the current market price of 7.86 USD,
Arcutis Biotherapeutics Inc
is
Undervalued by 40%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARQT
Relative Value
Base Case
13.1
USD
Undervaluation 40%
Valuation Multiples
Multiples Across Competitors
ARQT Competitors Multiples
Arcutis Biotherapeutics Inc Competitors
Arcutis Biotherapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
899.4m USD | 15.1 | -3.4 | -3.5 | -3.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.2 | 24.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
